Georgia vs Kyrgyzstan: Average cost of multi drug-resistant tuberculosis treatment
Georgia
1,600 constant 2022 US$
in 2022
Kyrgyzstan
1,607 constant 2022 US$
in 2022
Georgia rank
30th
Kyrgyzstan rank
29th
Average cost of multi drug-resistant tuberculosis treatment over time
- Georgia
- Kyrgyzstan
How they compare
Kyrgyzstan currently reports 1,607 constant 2022 US$ against 1,600 constant 2022 US$ in Georgia, a difference of 7 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Georgia ahead.
Georgia ranks 30th and Kyrgyzstan ranks 29th of 92 countries.
Georgia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Georgia | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,808 constant 2022 US$ | 1,564 constant 2022 US$ | 1,244 constant 2022 US$ | Georgia |
| 2020s | 2,096 constant 2022 US$ | 1,761 constant 2022 US$ | 335.67 constant 2022 US$ | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Georgia or Kyrgyzstan?
- Kyrgyzstan, at 1,607 constant 2022 US$ against 1,600 constant 2022 US$ in Georgia as of 2022.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Georgia and Kyrgyzstan?
- 7 constant 2022 US$, with Kyrgyzstan ahead.
- How many years of comparable data are there for Georgia and Kyrgyzstan?
- 5 years are reported by both, from 2018 to 2022.
- How do Georgia and Kyrgyzstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Georgia ranks 30th and Kyrgyzstan ranks 29th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.